JATT Acquisition priced its IPO of 12 million units at $10each, with each unit consisting of one Class A ordinary share and one-half of one redeemable warrant.
Units begin trading today on the NYSE under JATT U. Once the securities comprising the units begin separate trading, shares and warrants are expected to trade the NYSE under JATT and JATT WS.
The offering is expected to close July16.
JATT’s focus on the life sciences sector will emphasize companies utilizing the application of machine learning techniques and structure-based drug design to improve the therapeutic development process.
Dr. Someit Sidhu is CEO and director of the new SPAC. He is also the co-founder and CEO of Akaza Bioscience and the CEO of Izana Bioscience, as well as the co-founder of Pathios Therapeutics.
Raymond James is sole book-running manager for the offering. The underwriters have a 45-day option to purchase up to an additional 1.8 million units to cover any over-allotments. Read more.
